MedDataX Logo

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

NCT ID: NCT07093801

Last Updated: 2025-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-30

Study Completion Date

2029-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Castration Resistant Prostate Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Metastatic Castration Resistant Prostate Cancer (mCRPC) lutetium (177Lu) vipivotide tetraxetan

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients diagnosed with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan

Adult patients diagnosed with mCRPC eligible for and prescribed with lutetium (177Lu) vipivotide tetraxetan by the treating physician (Multidisciplinary Team).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

2. ≥ 18 years old at the time of enrollment.
3. Written informed consent must be obtained to participate to this study
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Asti, AT, Italy

Site Status RECRUITING

Novartis Investigative Site

Bergamo, BG, Italy

Site Status RECRUITING

Novartis Investigative Site

Brescia, BS, Italy

Site Status RECRUITING

Novartis Investigative Site

Catania, CT, Italy

Site Status RECRUITING

Novartis Investigative Site

Cona, FE, Italy

Site Status RECRUITING

Novartis Investigative Site

Foggia, FG, Italy

Site Status RECRUITING

Novartis Investigative Site

Florence, FI, Italy

Site Status RECRUITING

Novartis Investigative Site

Genova, GE, Italy

Site Status RECRUITING

Novartis Investigative Site

Genova, GE, Italy

Site Status RECRUITING

Novartis Investigative Site

Latina, LT, Italy

Site Status RECRUITING

Novartis Investigative Site

Macerata, MC, Italy

Site Status RECRUITING

Novartis Investigative Site

Milan, MI, Italy

Site Status RECRUITING

Novartis Investigative Site

Milan, MI, Italy

Site Status RECRUITING

Novartis Investigative Site

Rozzano, MI, Italy

Site Status RECRUITING

Novartis Investigative Site

Palermo, PA, Italy

Site Status RECRUITING

Novartis Investigative Site

Perugia, PG, Italy

Site Status RECRUITING

Novartis Investigative Site

Pisa, PI, Italy

Site Status RECRUITING

Novartis Investigative Site

Rionero in Vulture, PZ, Italy

Site Status RECRUITING

Novartis Investigative Site

Reggio Emilia, RE, Italy

Site Status RECRUITING

Novartis Investigative Site

Roma, RM, Italy

Site Status RECRUITING

Novartis Investigative Site

Roma, RM, Italy

Site Status RECRUITING

Novartis Investigative Site

Roma, RM, Italy

Site Status RECRUITING

Novartis Investigative Site

Roma, RM, Italy

Site Status RECRUITING

Novartis Investigative Site

La Spezia, SP, Italy

Site Status RECRUITING

Novartis Investigative Site

Torino, TO, Italy

Site Status RECRUITING

Novartis Investigative Site

Mestre, VE, Italy

Site Status RECRUITING

Novartis Investigative Site

Negrar, VR, Italy

Site Status RECRUITING

Novartis Investigative Site

Napoli, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Novartis Pharmaceuticals

Role: CONTACT

Phone: +41613241111

Email: [email protected]

Novartis Pharmaceuticals

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAAA617A1IT01

Identifier Type: -

Identifier Source: org_study_id